Cynapsus readies first human data of sublingual strip for PD

Cynapsus Therapeutics (TSX-V:CTH) is set to release human proof-of-concept data of its sublingual thin film-strip as a treatment for motor fluctuations, or episodes of immobility, in patients with Parkinson’s disease. “This will represent an important de-risking event for the project,” CEO Anthony Giovinazzo says in an exclusive interview with BioTuesdays.com, referring to the company’s APL-130277 [...]

Cynapsus confirms Parkinson’s treatment in drug trial

Cynapsus Therapeutics (TSX-V:CTH) has released positive top-line data from a human volunteer proof-of-concept trial for APL-130277, a sublingual thin film strip formulation of apomorphine, for the treatment of motor fluctuations or “off episodes” in Parkinson’s disease. The study showed a pharmacokinetic profile that compares favorably to injected apomorphine, with a mean T-max, or the time [...]

Cynapsus arranges debenture financing

Cynapsus Therapeutics (TSX-V:CTH) has arranged a financing of $229,885 of 10% of secured Series E-4 debentures due Dec. 30, 2012. As part of the financing, the company will pay a 13% capital discount to the debenture holders, resulting in net proceeds to Cynapsus of $200,000 and issue 800,000 common shares to the debenture holders at [...]

Cynapsus posts positive proof-of-concept results

Cynapsus Therapeutics (TSX-V:CTH) has obtained positive results in proof-of-concept studies comparing prototypes of its APL-130277 treatment for Parkinson’s disease with injectable apomorphine. “The achievement of this important milestone is crucial, as we believe these results have significantly de-risked the project, from the perspective of a sublingual thin film-strip delivering drug to the blood stream in [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Cynapsus sets testing of Parkinson’s drug

Cynapsus Therapeutics (TSX-V:CTH) plans to begin proof-of-concept studies comparing preliminary prototypes of APL-130277, its potential treatment for Parkinson’s disease, with injectable apomorphine near the end of the year. “This is an important milestone that is necessary before commencing human clinical studies in early 2011,” CEO Anthony Giovinazzo said in a statement. Among other developments, Cynapsus [...]

Cynapsus licenses in Parkinson’s drug

Cynapsus Therapeutics (TSX-V:CTH) has signed a license option agreement for all intellectual property  related to Adagio Pharmaceuticals’ APL-130277, a reformulation of an approved Parkinson’s drug. Under the accord, Adagio is entitled to receive 750,000 common shares of Cynapsus based on a price of 10 cents a share. A 12-month exclusive option period allows Cannasat to [...]

Cannasat changes name to Cynapsus Therapeutics

Cannasat Therapeutics (TSX-V:CTH) received shareholder approval to change its corporate name to Cynapsus Therapeutics, with no change to the stock symbol. In a statement, CEO Anthony Giovinazzo said the new name, which is drawn loosely from the word “synapse,” more accurately reflects the company’s new focus and direction on treatments for central nervous system diseases [...]